Lonapegsomatropin
Also known as: Lonapegsomatropin, lonapegsomatropin-tcgd, PEG-hGH prodrug, SKYTROFA, TransCon hGH
Source Lonapegsomatropin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lonapegsomatropin (SKYTROFA®) is a once‑weekly, pegylated prodrug of recombinant human growth hormone approved for treating growth hormone deficiency in children aged ≥1 year. By providing sustained release of somatropin, it aims to improve linear growth while reducing the injection burden compared with daily growth hormone therapy.
Mechanism of Action
Lonapegsomatropin is a pegylated prodrug that slowly releases native somatropin after subcutaneous injection. The released somatropin binds the growth hormone receptor on target tissues, activating the JAK2‑STAT5 signaling cascade and stimulating hepatic production of insulin‑like growth factor‑1 (IGF‑1). Elevated IGF‑1 promotes chondral proliferation and longitudinal bone growth, accounting for the observed increases in height velocity.
What the Research Shows
Phase‑3 data from the randomized, open‑label heiGHt trial (161 treatment‑naïve children) showed that once‑weekly lonapegsomatropin (0.24 mg hGH/kg/week) achieved a mean annualized height velocity of 11.2 cm/yr, statistically superior to daily somatropin (10.3 cm/yr) and produced a greater increase in height SDS over 52 weeks. The long‑term open‑label enliGHten extension (up to 6 years, n≈298) demonstrated sustained height SDS gains (mean –0.39 at year 4) and stable IGF‑1 SDS without new safety signals. Systematic reviews and network meta‑analyses that included lonapegsomatropin alongside other long‑acting GHs reported comparable efficacy and safety to daily GH, with no consistent advantage over other weekly formulations.
Reported Benefits
Clinical trials indicate that lonapegsomatropin can increase annual height velocity by roughly 0.9 cm/yr compared with daily growth hormone, leading to larger gains in height SDS after one year. The weekly dosing schedule reduces injection frequency, potentially improving adherence in children and families. Safety outcomes in trials were similar to daily GH, with mostly mild or moderate adverse events and no evidence of accelerated skeletal maturation or anti‑drug antibodies.
Limitations of the Evidence
Evidence beyond the 6‑year extension is limited, and long‑term rare adverse events remain uncharacterized. Indirect network meta‑analyses rely on heterogeneous study designs and do not provide head‑to‑head comparisons with other long‑acting GHs. The primary efficacy data stem from controlled trials in treatment‑naïve, pre‑pubertal children; extrapolation to older or previously treated patients is uncertain.
Safety Considerations
Adverse events reported in trials were generally mild to moderate, mirroring the profile of daily somatropin and included injection‑site reactions, transient headache, and mild hyperglycemia. No increase in skeletal maturation rate or formation of anti‑GH antibodies was observed. Routine monitoring of IGF‑1 levels and standard growth‑related safety parameters is recommended during therapy.
How It Is Administered
Lonapegsomatropin is administered by subcutaneous injection once weekly, typically at a dose of 0.24 mg hGH/kg/week as used in pivotal trials. The formulation is a pegylated prodrug that releases somatropin over several days, eliminating the need for daily injections.
Routes of Administration
Goals & Uses
- Normalization of IGF-1 levelsBiomarker / MetabolicHigh
- Adult growth hormone deficiency (investigational)EndocrinologyModerate
- Treatment of pediatric growth hormone deficiencyEndocrinology / GrowthHigh
- Improved treatment adherence via weekly dosingPatient Convenience / AdherenceHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Acute critical illnessCritical CareHigh
- Closed epiphyses (skeletal maturity)DevelopmentalModerate
- Closed epiphyses (for growth promotion indication)Pediatric / SkeletalModerate
- Hypersensitivity to somatropin or PEG componentsAllergy / ImmunologyHigh
- Diabetic retinopathyOphthalmologyModerate
- Prader-Willi syndrome with severe obesity or respiratory impairmentGenetic SyndromeHigh
Adverse Effects
- EdemaFluid BalanceUncommonSwelling from fluid retention
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Intracranial hypertension (benign)NeurologicalRare
- Joint pain (arthralgia)MusculoskeletalUncommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Elevated IGF-1 levels (above normal range)Endocrine / MetabolicCommon
- Slipped capital femoral epiphysisMusculoskeletalRare
- HypothyroidismEndocrineUncommon
Drug Interactions
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsModerate
- Cytochrome P450 substrates (e.g., cyclosporine, sex hormones, anticonvulsants)Low
- Insulin and antidiabetic agentsModerate
- Oral estrogenLow
- Thyroid hormone replacementModerate
Population Constraints
- Adults (off-label use)AdultRelative
- AdultsAdult PopulationRelative
- Patients with diabetes mellitusMetabolicRelative
- Pediatric patients with confirmed growth hormone deficiencyIndicationAbsolute
- Pediatric patients <1 year or weighing <11.5 kgPediatricAbsolute
- Patients with History of MalignancyOncologyRelative
Regulatory Status
- European UnionApprovedApproved: Pediatric growth hormone deficiencyEMA approval 2022
- United StatesApprovedApproved: Pediatric growth hormone deficiencyFDA approval 2021; marketed as Skytrofa
- United KingdomApprovedApproved: Pediatric growth hormone deficiencyMHRA approved following EMA decision; available in the UK market.
Approved by FDA (2021) as Skytrofa; EMA approval for pediatric GHD (2022).
Evidence & Sources
- Journal ArticleModerateManiatis AK, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateThornton PS, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighZhu J, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleHighde Fries Jensen L, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateLamb YN2022-01-01T00:00:00.000000Z
Frequently Asked Questions
How does lonapegsomatropin differ from daily growth hormone injections?
Lonapegsomatropin is a pegylated prodrug that releases somatropin gradually, allowing a single subcutaneous injection each week instead of daily shots. Clinical data show comparable safety and a modest increase in height velocity versus daily growth hormone.
What age and size criteria are required for treatment?
Regulatory approval specifies use in children at least 1 year old who weigh 11.5 kg or more and have documented growth hormone deficiency causing growth failure.
Is there a risk of the body developing antibodies against the drug?
In the long‑term extension study, no anti‑drug antibodies were detected, and the safety profile remained similar to daily growth hormone, suggesting low immunogenicity.
Can lonapegsomatropin be used in children who have already received daily GH?
The pivotal trials enrolled treatment‑naïve children; data on switching from daily to weekly therapy are limited, so clinicians should consider individual patient factors and monitor response closely.
What monitoring is needed while on lonapegsomatropin?
Standard monitoring includes periodic measurement of height, growth velocity, IGF‑1 levels, and assessment for adverse events such as injection‑site reactions or abnormal glucose metabolism.
What is Lonapegsomatropin?
Lonapegsomatropin (SKYTROFA®) is a once‑weekly, pegylated prodrug of recombinant human growth hormone approved for treating growth hormone deficiency in children aged ≥1 year. By providing sustained release of somatropin, it aims to improve linear growth while reducing the injection burden compared with daily growth hormone therapy.
What is Lonapegsomatropin used for?
Lonapegsomatropin is educationally associated with: Normalization of IGF-1 levels, Adult growth hormone deficiency (investigational), Treatment of pediatric growth hormone deficiency, Improved treatment adherence via weekly dosing. Educational only — not medical advice.
How is Lonapegsomatropin administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Lonapegsomatropin?
Reported adverse effects include: Edema, Hyperglycemia, Intracranial hypertension (benign), Joint pain (arthralgia), Injection site reactions, Headache, Elevated IGF-1 levels (above normal range), Slipped capital femoral epiphysis, Hypothyroidism. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lonapegsomatropin?
Recorded contraindications: Active malignancy, Acute critical illness, Closed epiphyses (skeletal maturity), Closed epiphyses (for growth promotion indication), Hypersensitivity to somatropin or PEG components, Diabetic retinopathy, Prader-Willi syndrome with severe obesity or respiratory impairment. Consult a qualified clinician before use.